AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39303200
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg once every 2 weeks for up to 12 doses)
Trial: 39304237
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric carboxymaltose (20 mg/kg to a maximum of 1000 mg)
Trial: 39304237
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulphate (200 mg; 65 mg elemental iron) three times daily until 6 weeks postpartum
Trial: 39304241
Drug: Subcutaneous efgartigimod
RxNorm normalized name: Efgartigimod alfa
DrugBank: Efgartigimod alfa (DB15270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous efgartigimod PH20 (1000 mg weekly for a maximum of 48 weeks)
Trial: 39304241
Drug: Subcutaneous efgartigimod
RxNorm normalized name: Efgartigimod alfa
DrugBank: Efgartigimod alfa (DB15270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous efgartigimod PH20
Trial: 39304797
Drug: Combined androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined androgen blockade (CAB) with goserelin (10.8 mg/3m) and bicalutamide (50 mg/OD)
Trial: 39304797
Drug: Combined androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined androgen blockade (CAB) with goserelin (10.8 mg/3m), bicalutamide (50 mg/OD), and dutasteride (0.5 mg/OD)
Trial: 39304797
Drug: Combined androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined androgen blockade (CAB) with goserelin, bicalutamide, and dutasteride (0.5 mg/OD) in patients with disease progression after prior CAB therapy
Trial: 39304918
Drug: standard in-person
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard in-person treatment as usual
Trial: 39305031
Drug: Fast-acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-acting insulin therapy
Trial: 39305035
Drug: Individualised comprehensive
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised comprehensive physical therapy
Trial: 39305160
Drug: vosoritide (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vosoritide (15 μg/kg/day)
Trial: 39305436
Drug: Atomoxetine (ato)
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine (ato) 80 mg
Trial: 39305436
Drug: Atomoxetine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine and spironolactone (ato-spiro) 80/50 mg
Trial: 39305441
Drug: Relacorilant (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relacorilant (100-200 mg/day for up to 12 weeks or 250-400 mg/day for up to 16 weeks)
Trial: 39305562
Drug: Cytokine release
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytokine release syndrome (CRS) treatment
Trial: 39305562
Drug: Immune effector
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune effector cell-associated neurotoxicity syndrome (ICANS) treatment
Trial: 39305910
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) followed by two cycles of 200 mg intravenous PD-1 inhibitor, tislelizumab, plus platinum-based chemotherapy.
Trial: 39305913
Drug: Glucocorticoids in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoids in combination with immunosuppressive agents or intravenous immunoglobulin
Trial: 39306346
Drug: Apixaban at
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban at a reduced dose of 2.5 mg two times per day
Trial: 39306346
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy adjusted to INR target (2-3)
Trial: 39306350
Drug: First-line cessation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line cessation medications
Trial: 39306468
Drug: Liver transplantation
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liver transplantation plus chemotherapy
Trial: 39306585
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg i.v. every 2 weeks or every 3 weeks for ≤2 years
Trial: 39306585
Drug: Ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 3 mg/kg i.v. every 3 weeks for four cycles
Trial: 39306592
Drug: Mandibular advancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular advancement devices (MAD) treatment for OSA, two-piece adjustable appliances, standardized protocol, duration of six years.
Trial: 39306592
Drug: Mandibular advancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular advancement devices (MAD) treatment for OSA.
Trial: 39306601
Drug: Modafinil 200
RxNorm normalized name: modafinil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil 200 mg twice daily
Trial: 39306601
Drug: Amphetamine-dextroamphetamine 20
RxNorm normalized name: amphetamine-dextroamphetamine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine-dextroamphetamine 20 mg twice daily
Trial: 39306798
Drug: BQT (bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQT (bismuth quadruple therapy) - 14-day therapy with b.i.d. proton pump inhibitor 20 mg, bismuth 220 mg, tetracycline 400 mg q.i.d, metronidazole 400 mg q.i.d
Trial: 39306798
Drug: PBMn (minocycline-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBMn (minocycline-containing therapy) - 14-day therapy with b.i.d. proton pump inhibitor 20 mg, minocycline 50 mg q.i.d, metronidazole 400 mg q.i.d
Trial: 39306923
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg intravenously every three weeks
Trial: 39307154
Drug: Memantine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 20 mg once a day
Trial: 39307154
Drug: Trazodone 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 200 mg once a day
Trial: 39309703
Drug: AVATAR-based video
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVATAR-based video immersion with radiation therapy
Trial: 39309726
Drug: Personalised remote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalised remote speech therapy for 8 weeks
Trial: 39310045
Drug: CONNECTDROP® Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CONNECTDROP® Medication Event Monitoring System (MEMS) paired with a smartphone application
Trial: 39310667
Drug: Higher-protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-protein diet (HP; ∼38% of daily intake as protein)
Trial: 39310667
Drug: Normal-protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-protein diet (NP; ∼15% of daily intake as protein)
Trial: 39310666
Drug: OC+P (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC+P (50 g prunes daily)
Trial: 39310769
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow aspirate concentrates (BMACs) from knee-OA patients; specific dosage and duration not mentioned.
Trial: 39311597
Drug: Long-acting injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting injectable cabotegravir (CAB-LA) 600 mg
Trial: 39312625
Drug: Tactile massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tactile massage (TM) for 15 minutes, twice a week for 4 weeks
Trial: 39313288
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose dCRT prescribed carboplatin/paclitaxel or cisplatin/capecitabine
Trial: 39313288
Drug: Escalated dose
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated dose dCRT prescribed carboplatin/paclitaxel or cisplatin/capecitabine
Trial: 39313594
Drug: Cetuximab (Cetux)
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab (Cetux) + chemotherapy
Trial: 39313857
Drug: Inactivated COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated COVID-19 vaccine (CoronaVac®) co-administered with inactivated enterovirus type 71 vaccine (Inlive®)
Trial: 39314107
Drug: Pharmacologic agents
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic agents (e.g., botulinum toxin type A, injectable fillers, chemical peels)
Trial: 39314125
Drug: Standard HepB3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard HepB3 vaccine series (group U3)
Trial: 39315864
Drug: BRAF/MEK inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRAF/MEK inhibitors (encorafenib and binimetinib) followed by immune checkpoint inhibitors (ipilimumab and nivolumab)
Trial: 39315864
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (ipilimumab and nivolumab) followed by BRAF/MEK inhibitors (encorafenib and binimetinib)
Trial: 39315864
Drug: BRAF/MEK inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRAF/MEK inhibitors (encorafenib and binimetinib) for 8 weeks followed by immune checkpoint inhibitors (ipilimumab and nivolumab) and retreatment with BRAF/MEK inhibitors
Trial: 39315892
Drug: RISA-PE stage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RISA-PE stage B (A + serum lactate >2 mmol/L OR shock index ≥1)
Trial: 39316400
Drug: Voice-activated, internet-delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice-activated, internet-delivered cognitive behavioral therapy for insomnia (CBT-I) program for 6 weeks
Trial: 39316768
Drug: Decitabine and
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine and venetoclax (low-dose regimen)
Trial: 39317492
Drug: SOC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC with early high-dose intravenous vitamin C (200 mg/kg per day, within 6 hours after return of spontaneous circulation, for 3 days)
Trial: 39317492
Drug: SOC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC with early high-dose intravenous vitamin C
Trial: 39317633
Drug: Niraparib 200
RxNorm normalized name: niraparib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 200 mg and abiraterone acetate 1000 mg plus prednisone 10 mg (AAP)
Trial: 39317994
Drug: Motor Interference
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motor Interference Therapy (MIT)
Trial: 39318595
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (discontinued empirical anti-MRSA therapy if nasal swab result is negative)
Trial: 39318595
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (empirical treatment with linezolid or vancomycin)
Trial: 39318719
Drug: Microbial inulinase
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microbial inulinase supplementation (2000 inulinase activity units, twice daily for 4 weeks)
Trial: 39318788
Drug: RMC-035 (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMC-035 (1.3 or 0.65 mg/kg)
Trial: 39319279
Drug: Esomeprazole 10
RxNorm normalized name: esomeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 10 mg/day for patients weighing 10-20 kg (Group 1)
Trial: 39319279
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg/day for patients weighing ≥20 kg (Group 2)
Trial: 39319279
Drug: Esomeprazole 10
RxNorm normalized name: esomeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 10 mg/day for patients previously diagnosed with GU and/or DU (Group 3)
Trial: 39319279
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg/day for patients previously diagnosed with GU and/or DU (Group 4)
Trial: 39319356
Drug: Prescription Digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription Digital Therapeutic (PDT; Somryst)
Trial: 39320397
Drug: Surgeon behaviors
RxNorm normalized name: sturgeon, unspecified preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgeon behaviors (e.g., establishing rapport, providing reassuring information)
Trial: 39320879
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care with standardized tiered fever treatment on occurrence of temperature of 38 °C or greater.
Trial: 39320906
Drug: Lenvatinib, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib, dosage and duration not specified
Trial: 39320907
Drug: Crisugabalin 40
RxNorm normalized name: Crisugabalin
DrugBank: Crisugabalin (DB19300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisugabalin 40 mg/d
Trial: 39320907
Drug: Crisugabalin 80
RxNorm normalized name: Crisugabalin
DrugBank: Crisugabalin (DB19300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisugabalin 80 mg/d
Trial: 39321363
Drug: Tulisokibart (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tulisokibart (1000 mg on day 1 and 500 mg at weeks 2, 6, and 10)
Trial: 39321361
Drug: Ziresovir (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziresovir (10 to 40 mg, according to body weight), administered twice daily for 5 days
Trial: 39321361
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered twice daily for 5 days
Trial: 39321453
Drug: Web-based weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based weekly survey for out-of-pocket costs
Trial: 39321757
Drug: Integrated Stepped
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Integrated Stepped Alcohol Treatment with Contingency Management (ISAT + CM)
Trial: 39322237
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (n=189) - provided by GPs through brief counselling and psychotropic medication prescriptions
Trial: 39322526
Drug: High remnant
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High remnant cholesterol (> 20.5 mg/dL; n = 1,116)
Trial: 39322526
Drug: Intermediate remnant
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate remnant cholesterol (14‒20.5 mg/dL; n = 1,031)
Trial: 39322526
Drug: Low remnant
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low remnant cholesterol (≤14.0 mg/dL; n = 1,201)
Trial: 39322526
Drug: On-treatment remnant-C
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment remnant-C cut-off of 17 mg/dL (median)
Trial: 39322526
Drug: Achieving LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achieving LDL-C <55 or 70 mg/dL
Trial: 39322802
Drug: CT-P17 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P17 (100 mg/mL), citrate-free adalimumab biosimilar
Trial: 39322802
Drug: R-ADA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-ADA (100 mg/mL)
Trial: 39322802
Drug: ADA-BioS (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADA-BioS (50 mg/mL)
Trial: 39322802
Drug: Previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment with ADA-BioS
Trial: 39322802
Drug: Previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment with pain at injection site
Trial: 39322802
Drug: CT-P17 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P17 treatment
Trial: 39322961
Drug: Erenumab (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab (70 mg or 140 mg) for migraine prophylaxis over 128 weeks.
Trial: 39322961
Drug: Erenumab treatment
RxNorm normalized name: erenumab
DrugBank: Erenumab (DB14039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Erenumab treatment after drug holiday.
Trial: 39322961
Drug: Drug holiday
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug holiday (voluntary treatment interruption of up to 24 weeks).
Trial: 39324933
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen (HBO2) treatment
Trial: 39325452
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) - weekly group or individual counseling
Trial: 39325452
Drug: Digital CBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital CBT (CBT4CBT) plus brief weekly clinical monitoring
Trial: 39325453
Drug: Tongxinluo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongxinluo (4 oral capsules, 3 times a day for 90 days)
Trial: 39325453
Drug: Control (placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo, 4 oral capsules, 3 times a day for 90 days)
Trial: 39325463
Drug: Oral everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral everolimus 1.5-mg daily for 42 days after surgery
Trial: 39325510
Drug: Ambulatory cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory cognitive tests administered via smartphone app 4 times per day during a 14-day data collection period.
Trial: 39325643
Drug: Losartan 25-100
RxNorm normalized name: losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan 25-100 mg/day orally
Trial: 39325787
Drug: Continued medical
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued medical treatment of CRS
Trial: 39326356
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume ≥7 mL/kg PBW
Trial: 39326356
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume <7 mL/kg PBW
Trial: 39326908
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (12 weeks)
Trial: 39326908
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (APM and exercise therapy)
Trial: 39326918
Drug: Selexipag (200-1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selexipag (200-1600 µg twice daily titration until individual maximum tolerated dose) + standard of care
Trial: 39327056
Drug: Higher post-filter
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher post-filter ionised calcium target (0.35-0.45 mmol/L)
Trial: 39327056
Drug: Lower post-filter
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower post-filter ionised calcium target (0.25-0.35 mmol/L)
Trial: 39327294
Drug: Polypectomy repeated
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypectomy repeated twice during the withdrawal phase after initial insertion of the colonoscope (study group).
Trial: 39327433
Drug: Surufatinib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib (200 mg, qd, po) plus toripalimab (240 mg, d1, ivdrip) combined with etoposide (100 mg/m², d1-d3, iv, drip) and cisplatin (25 mg/m², d1-d3, ivdrip)
Trial: 39327563
Drug: One session
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One session of low-level laser therapy (LLLT) per week for 4 weeks
Trial: 39327563
Drug: Two sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two sessions of low-level laser therapy (LLLT) per week for 4 weeks
Trial: 39327563
Drug: Three sessions
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three sessions of low-level laser therapy (LLLT) per week for 4 weeks
Trial: 39328096
Drug: Ritlecitinib 50
RxNorm normalized name: ritlecitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib 50 or 30 mg (± 4-week 200-mg loading dose) for 24 weeks
Trial: 39328096
Drug: Ritlecitinib 50
RxNorm normalized name: ritlecitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib 50 or 30 mg for 24 weeks
Trial: 39328391
Drug: Treatment expectation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment expectation measurements
Trial: 39328832
Drug: Video-guided active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video-guided active breaks through the 'Active Classes' web platform, lasting 5-10 minutes, moderate to vigorous intensity, twice a day, for 12 weeks.
Trial: 39328960
Drug: Cannabis cream
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis cream
Trial: 39329272
Drug: DNG/EE treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNG/EE treatment